Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now?

Vertex Pharmaceuticals (NASDAQ: VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and this platform has helped it generate billions of dollars in earnings. But Vertex now is showing that it also can be a game changer when it comes to treating one of the most common of health problems -- pain.The biotech just won regulatory approval for Journavx (formerly known as suzetrigine) for the treatment of acute pain -- the sort of pain you may have after an accident or surgery. The charm of this drug is it delivers excellent pain control without the addiction risk associated with opioid painkillers. The prescription of opioids has resulted in a significant burden for the U.S. healthcare system, with the opioid crisis costing $631 billion from 2015 through 2018, according to a Society of Actuaries report.Today, with this new Vertex option available, is this biotech player a no-brainer buy?Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool